A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. (2016)
Attributed to:
Establishment of the Cambridge Single Cell Analysis Clinical Core Facility [SCACCF]
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.205
Publication URI: https://www.repository.cam.ac.uk/handle/1810/256264
Type: Journal Article/Review